477 related articles for article (PubMed ID: 26416777)
1. What are the best predictors for successful GnRH antagonist protocol in in vitro fertilization (IVF) treatment?
Samara N; Reis D; Danielli Miller N; Ghetler Y; Berkovitz A; Miller M; Gonen O; Shulman A; Wiser A
Gynecol Endocrinol; 2015; 31(11):877-9. PubMed ID: 26416777
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
3. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
4. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction-intrauterine insemination to in vitro fertilization conversions, independent of age and estradiol level on the day of human chorionic gonadotropin administration.
Quaas AM; Missmer SA; Ginsburg ES
Fertil Steril; 2010 Feb; 93(2):605-8. PubMed ID: 19324340
[TBL] [Abstract][Full Text] [Related]
6. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
Younis JS; Izhaki I; Ben-Ami M
Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
8. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
Dahan MH; Agdi M; Shehata F; Son W; Tan SL
Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
[TBL] [Abstract][Full Text] [Related]
9. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
10. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
[TBL] [Abstract][Full Text] [Related]
11. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
[TBL] [Abstract][Full Text] [Related]
14. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
15. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
[TBL] [Abstract][Full Text] [Related]
17. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
18. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
[TBL] [Abstract][Full Text] [Related]
19. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzis BC; Tournaye H; Devroey P
Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
[TBL] [Abstract][Full Text] [Related]
20. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
